- Home
- WOLF vs SLBT Comparison
WOLF vs SLBT Comparison
Compare WOLF & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WOLF | SLBT |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | 20 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | WOLF | SLBT |
|---|---|---|
| Price | $29.62 | $4.41 |
| Analyst Decision | Sell | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 236.9K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $1.16 | $3.23 |
| 52 Week High | $80.82 | $6.25 |
Technical Indicators
Market Signals| Indicator | WOLF | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 47.45 |
| Support Level | $15.86 | $3.63 |
| Resistance Level | $31.99 | $4.91 |
| Average True Range (ATR) | 4.19 | 0.74 |
| MACD | -0.91 | -0.03 |
| Stochastic Oscillator | 7.78 | 32.12 |
Price Performance
Historical ComparisonAbout WOLF Wolfspeed Inc.
Wolfspeed Inc develops and manufactures semiconductor technologies based on silicon carbide (SiC) for power electronics applications. Its product portfolio includes SiC MOSFETs, Schottky diodes, and power modules used in power electronics applications. The company also provides reference designs, evaluation kits, and gate driver boards to support the development and integration of its SiC products across industries such as electric vehicles, renewable energy, and industrial systems.
About SLBT SL Science Holding Limited Ordinary Shares
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.